Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer.

Transl Oncol · 2015 · PMC4350637 · PMID 25749176

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

In patients whose tumors carried wild-type PIK3CA , erlotinib plus GEMOX showed a favorable trend for overall response, but no statistically significance difference ( P = .08).

also in 1,053 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.